Search results for "Ethanolamine"

showing 10 items of 122 documents

Coiled-Coil Lipopeptides Mimicking the Prehairpin Intermediate of Glycoprotein gp41

2009

Protein ConformationMolecular Sequence DataRetroviridae ProteinsPeptideGp41CatalysisLipopeptides03 medical and health sciences0302 clinical medicineAnimalsAmino Acid Sequence030304 developmental biologychemistry.chemical_classificationCoiled coil0303 health sciencesMembrane GlycoproteinsPhosphatidylethanolaminesMolecular MimicryGeneral ChemistryGeneral MedicineVirus InternalizationAnti-Retroviral AgentschemistryBiochemistryPhosphatidylcholinesGlycoprotein030217 neurology & neurosurgeryAngewandte Chemie
researchProduct

Efficacy of a fixed combination of ciclesonide and formoterol: the EXCITED-study.

2011

SummaryRecommended treatment for moderate to severe asthma is the combination of an inhaled corticosteroid and a long-acting beta2-agonist. The present study was designed to evaluate the efficacy of a newly developed fixed combination of ciclesonide and formoterol in comparison to the marketed fixed combination of fluticasone and salmeterol in patients with moderate asthma.This was a phase II, multi-centre, randomized, parallel-group, double-blind, double-dummy study. After a 2-week run-in period, 160 patients with moderate asthma were randomized to a 6-week treatment with ciclesonide/formoterol 320/9 μg bid (CIC/F) or fluticasone propionate/salmeterol 250/50 μg bid (FP/S), both delivered a…

Pulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtyAdolescentUrologyCiclesonideCiclesonideFluticasone propionatechemistry.chemical_compoundYoung AdultDouble-Blind Methodimmune system diseasesPregnenedionesForced Expiratory VolumeFormoterol FumarateGermanyAdministration InhalationmedicineHumansFixed combinationAlbuterolFormoterolAnti-Asthmatic AgentsChildGlucocorticoidsFluticasoneAgedFluticasone-Salmeterol Drug Combinationbusiness.industryrespiratory systemMiddle AgedAsthmaFluticasone-Salmeterol Drug Combinationrespiratory tract diseasesBronchodilator AgentsAndrostadienesDrug CombinationsTreatment OutcomeTolerabilitychemistryEthanolaminesAustriaFormoterol FumarateFemaleSalmeterolFormoterolbusinessmedicine.drugRespiratory medicine
researchProduct

Fluticasone/formoterol combination therapy versus budesonide/formoterol for the treatment of asthma: a randomized, controlled, non-inferiority trial …

2012

The inhaled corticosteroid fluticasone propionate (fluticasone) and the long-acting β₂ agonist formoterol fumarate (formoterol) have been combined in a single aerosol inhaler fluticasone/formoterol (flutiform(®)). This study compared the efficacy and safety of fluticasone/formoterol with the combination product budesonide/formoterol (Symbicort(®) Turbohaler(®)).A randomized, double-blind, double-dummy, multicenter, Phase 3 study comprising a 7- (± 3) day screening, 2-4-week run-in, and 12-week treatment periods. Patients aged ≥ 12 years with moderate to severe persistent asthma for ≥ 6 months before screening and forced expiratory volume in one second (FEV₁) 50-80% predicted and ≥ 15% rever…

Pulmonary and Respiratory MedicineBudesonideAdultMaleAdolescentFluticasone propionateYoung AdultDouble-Blind Methodimmune system diseasesForced Expiratory VolumeFormoterol FumarateAdministration InhalationImmunology and AllergyMedicineHumansBudesonideFluticasoneAgedbusiness.industryInhalerDry Powder Inhalersrespiratory systemMiddle AgedAsthmarespiratory tract diseasesBronchodilator AgentsAndrostadienesDrug CombinationsBudesonide/formoterolEthanolaminesAnesthesiaPediatrics Perinatology and Child HealthSalbutamolFluticasoneFormoterol FumarateFemaleFormoterolbusinesshormones hormone substitutes and hormone antagonistscirculatory and respiratory physiologymedicine.drugThe Journal of asthma : official journal of the Association for the Care of Asthma
researchProduct

Is the patient's baseline inhaled steroid dose a factor for choosing the budesonide/formoterol maintenance and reliever therapy regimen?

2011

Objective: Baseline inhaled corticosteroid (ICS) dose may be a factor for prescribers to consider when they select a budesonide/formoterol maintenance and reliever therapy regimen for symptomatic asthmatics. Methods: A 6-month randomized study compared two maintenance doses of budesonide/formoterol 160/4.5 µg, 1 × 2 and 2 × 2, plus as needed, in 8424 asthma patients with symptoms when treated with ICS ± an inhaled long-acting β2-agonist (LABA). In the total study population, 1339 (17%) were high-dose ICS (HD) users (≥1600 µg/day budesonide). This HD stratum was compared with the rest of the study population, divided into low-dose (LD; 400 µg/day) and medium-dose strata (MD; 401–1599 µg/day…

Pulmonary and Respiratory MedicineBudesonideAdultMalemedicine.medical_specialtyTime FactorsAdolescentmedicine.drug_classSeverity of Illness Indexlaw.inventionYoung AdultRandomized controlled triallawAdrenal Cortex HormonesInternal medicineSurveys and QuestionnairesAdministration InhalationmedicineBudesonide Formoterol Fumarate Drug CombinationHumansPharmacology (medical)Anti-Asthmatic AgentsBudesonideAsthmaAgedlcsh:RC705-779Aged 80 and overDose-Response Relationship Drugbusiness.industrylcsh:Diseases of the respiratory systemMiddle Agedmedicine.diseaseAsthmaRegimenDrug CombinationsTreatment OutcomeBudesonide/formoterolAsthma Control QuestionnaireEthanolaminesAnesthesiaCorticosteroidFemaleFormoterolbusinessmedicine.drugTherapeutic advances in respiratory disease
researchProduct

The effect of budesonide/formoterol maintenance and reliever therapy on the risk of severe asthma exacerbations following episodes of high reliever u…

2012

Abstract Background Divergent strategies have emerged for the management of severe asthma. One strategy utilises high and fixed doses of maintenance treatment, usually inhaled corticosteroid/long-acting β2-agonist (ICS/LABA), supplemented by a short-acting β2-agonist (SABA) as needed. Alternatively, budesonide/formoterol is used as both maintenance and reliever therapy. The latter is superior to fixed-dose treatment in reducing severe exacerbations while achieving similar or better asthma control in other regards. Exacerbations may be reduced by the use of budesonide/formoterol as reliever medication during periods of unstable asthma. We examined the risk of a severe exacerbation in the per…

Pulmonary and Respiratory MedicineBudesonideExacerbationAsthma in primary careSeverity of Illness Indexlaw.inventionRandomized controlled trialDouble-Blind MethodlawAdrenal Cortex HormonesRisk FactorsFormoterol FumarateAdministration InhalationmedicineBudesonide Formoterol Fumarate Drug CombinationHumansAnti-Asthmatic AgentsBudesonideAsthmalcsh:RC705-779Maintenance dosebusiness.industryResearchlcsh:Diseases of the respiratory systemmedicine.diseaseAsthmaBronchodilator AgentsDrug CombinationsTreatment OutcomeBudesonide/formoterolEthanolaminesAnesthesiaDisease ProgressionFormoterol FumarateDrug Therapy CombinationFormoterolbusinesshormones hormone substitutes and hormone antagonistsmedicine.drugRespiratory research
researchProduct

Nanocomplexes for gene therapy of respiratory diseases: Targeting and overcoming the mucus barrier

2015

Gene therapy, i.e. the delivery and expression of therapeutic genes, holds great promise for congenital and acquired respiratory diseases. Non-viral vectors are less toxic and immunogenic than viral vectors, although they are characterized by lower efficiency. However, they have to overcome many barriers, including inflammatory and immune mediators and cells. The respiratory and airway epithelial cells, the main target of these vectors, are coated with a layer of mucus, which hampers the effective reaching of gene therapy vectors carrying either plasmid DNA or small interfering RNA. This barrier is thicker in many lung diseases, such as cystic fibrosis. This review summarizes the most impor…

Pulmonary and Respiratory MedicineCystic FibrosisGenetic enhancementContext (language use)Gene deliveryVectors in gene therapyPolyethylene GlycolsViral vectorPolyethyleinimine Poly-L-lysine Ethylene glycol Chitosan PAMAM G0 dendrimer N-(1-(23-Dioleyloxy)propyl)-NNNtrimethylammonium chloride 12-Dioleoylphosphatidylethanolamine N-acetylcystein 12-Dioctadecanoyl-sn-glycero-3-phosphoethanolaminemedicineHumansTechnology PharmaceuticalPharmacology (medical)RNA Small InterferingLungExpectorantsInflammationLungbusiness.industryBiochemistry (medical)Gene Transfer TechniquesGenetic TherapyMucusMucusmedicine.anatomical_structureSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoImmunologyNanoparticlesInflammation MediatorsbusinessPlasmidsRespiratory tract
researchProduct

Mboat7 down-regulation by hyper-insulinemia induces fat accumulation in hepatocytes.

2020

Background: Naturally occurring variation in Membrane-bound O-acyltransferase domain-containing 7 (MBOAT7), encoding for an enzyme involved in phosphatidylinositol acyl-chain remodelling, has been associated with fatty liver and hepatic disorders. Here, we examined the relationship between hepatic Mboat7 down-regulation and fat accumulation. Methods: Hepatic MBOAT7 expression was surveyed in 119 obese individuals and in experimental models. MBOAT7 was acutely silenced by antisense oligonucleotides in C57Bl/6 mice, and by CRISPR/Cas9 in HepG2 hepatocytes. Findings: In obese individuals, hepatic MBOAT7 mRNA decreased from normal liver to steatohepatitis, independently of diabetes, inflammatio…

Research paperTGFβ Transforming Growth Factor BetaIntracellular SpaceCRISPR Clustered Regularly Interspaced Short Palindromic RepeatshHEPS Human HepatocytesMice0302 clinical medicineLPIAT1DAG Diacylglyceroli.p. Intraperitonealmedia_commonFatty AcidsGeneral Medicine3. Good health030220 oncology & carcinogenesisHOMA-IR homeostasis Model Assessment of Insulin ResistanceMPO morpholinolcsh:Medicine (General)medicine.medical_specialtyPE Phosphatidyl-EthanolamineNashGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesTNFα tumor Necrosis Factor AlphaLDL Low Density LipoproteinsHyperinsulinismNAFLDSD Standard Dietmedia_common.cataloged_instanceHumansCPT1 Carnitine Palmitoyltransferase IPhosphatidylinositolGene SilencingEuropean unionVLDL Very Low Density Lipoproteinlcsh:RhHSC Human Hepatic Stellate Cellsmedicine.diseaseLipid MetabolismOA Oleic AcidCI Confidence IntervalMboat7 Membrane bound O-acyltransferase domain containing 7MCD methionine choline deficient diet030104 developmental biologyEndocrinologychemistryCDP Cytidine-DiphosphateFOXO1 Forkhead Box protein O1NAFLD nonalcoholic fatty liver diseaseSteatohepatitisBMI Body Mass IndexCL CardiolipinAcyltransferases0301 basic medicineAlcoholic liver diseaseCXCL10 C-X-C Motif Chemokine 10lcsh:Medicinechemistry.chemical_compoundNon-alcoholic Fatty Liver DiseaseIFG Impaired Fasting GlucoseAPOB Apolipoprotein BNonalcoholic fatty liver diseasePIP Phosphatidyl-Inositol-PhosphateSteatohepatitisqRT-PCR quantitative Real Time Polymerase Chain ReactionMice Knockoutlcsh:R5-920ORO Oil Red O StainingPI PhosphatidylinositolFatty liverTM6SF2 Transmembrane 6 Superfamily Member 2PhospholipidTAG TriglyceridesNASH Nonalcoholic SteatohepatitisLipogenesisLPA Lyso-Phosphatidic AcidPhosphatidylinositolSignal TransductionPS Phosphatidyl-SerinePA Palmitic AcidALD alcoholic liver diseasePC Phosphatidylcholinei.v. IntravenousFATP1 Fatty Acid Transport Protein 1Models BiologicalInternal medicinemedicineAnimalsNonalcoholic fatty liver diseasePPARα Peroxisome Proliferator-Activated Receptor alphaObesityG3P Glyceraldehyde-3-PhosphateSREBP1c Sterol Regulatory Element-Binding Protein 1HDL High Density Lipoproteinsbusiness.industryPI3K Phosphatidylinositol 3 KinaseMembrane ProteinsNHEJ Non-Homologues End JoiningPNPLA3 Patatin-like Phospholipase Domain-containing-3MTTP Microsomal Triglyceride Transfer ProteinLPIAT1 Lysophosphatidylinositol Acyltransferase 1TMC4 Transmembrane Channel-Like 4Disease Models AnimalGene Expression RegulationHepatocytesFOXA2 Forkhead Box A2mTOR mammalian target of RapamycinSteatosisInsulin ResistancebusinessPG Phosphatidyl-GlycerolFABP1 Fatty Acid-Binding Protein 1 FAS Fatty Acid SynthaseT2DM Type 2 Diabetes MellitusEBioMedicine
researchProduct

POLYMERIC MICELLES BASED ON A PHOSPHOLIPID/ POLYASPARTAMIDIC COPOLYMER FOR BECLOMETHASONE DIPROPIONATE DELIVERY TO THE LUNGS

2010

Settore CHIM/09 - Farmaceutico Tecnologico Applicativoalphabeta-poly(N-2-hydroxyethyl)-DL-aspartamide (PHEA) 12-Distearoyl-sn-glycero-3-Phosphoethanolamine-N-[Amino(Polyethylene glycol)2000] (DSPE-PEG2000-NH2) polymeric micelles drug delivery beclomethasone dipropionate (BDP) pulmonary diseases.
researchProduct

Dioxidomolybdenum(VI) and -tungsten(VI) complexes with tripodal amino bisphenolate ligands as epoxidation and oxo-transfer catalysts

2017

The molybdenum(VI) and tungsten(VI) complexes [MO2(L)] (M = Mo (1), W (2), H2L = bis(2-hydroxy-3,5-di-tert-butybenzyl)morpholinylethylamine) were synthesized and the complexes were used to catalyze oxotransfer reactions, viz. sulfoxidation, epoxidation and benzoin oxidation. For comparison, the same reactions were catalyzed using the known complexes [MO2(L′)] (M = Mo (3), W (4), H2L′ = bis(2-hydroxy-3,5-di-tert-butybenzyl)ethanolamine) and [MO2(L″)] (M = Mo (5), W (6), H2L″ = bis(2-hydroxy-3,5-di-tert-butybenzyl)diethyleneglycolamine). The oxo atom transfer activity between DMSO and benzoin at 120 °C was identical for all studied catalysts. Reasonable catalytic activity was observed for sul…

Solid-state chemistrytungstenchemistry.chemical_elementTungsten010402 general chemistry01 natural sciencesMedicinal chemistryepoxysulfoxidationCatalysisInorganic Chemistrychemistry.chemical_compoundEthanolaminemolybdenumBenzoinepoxidationMaterials ChemistryOrganic chemistryoxygen atom transferPhysical and Theoretical Chemistryta116atoms010405 organic chemistryLow activityepoksivolframi0104 chemical sciencesoxotransfer reactionsatomithappichemistryMolybdenummolybdeenioxygenPolyhedron
researchProduct

CCDC 162028: Experimental Crystal Structure Determination

2002

Related Article: V.Tudor, V.Kravtsov, M.Julve, F.Lloret, Y.A.Simonov, J.Lipkowski, V.Buculei, M.Andruh|2001|Polyhedron|20|3033|doi:10.1016/S0277-5387(01)00906-8

Space GroupCrystallographyCrystal SystemCrystal Structure(mu2-44'-Bipyridine-NN')-bis(triethanolamine-NOO'O'')-di-copper(ii) diperchlorate trihydrateCell ParametersExperimental 3D Coordinates
researchProduct